Abstract: This invention describes a product obtained from the isolation and concentration of specific immunoglobulins (antibodies) derived from the mammary secretions of cows immunized with Helicobacter pylori. The product is useful in preparing formulations for the treatment and/or prevention of gastric diseases.

Abstract: A human monoclonal antibody, which has prophylactic and therapeutic effect to infections diseases caused by Pseudomonas aeruginosa, and the epitope of which is located in the outer core moiety of LPS of the microorganism. A hybridoma producing the human monoclonal antibody, and processes for preparing the antibody and hybridoma are also provided.

Abstract: Antibodies which form immune complexes with human native prothrombin only, in the presence of mixtures of human native prothrombin and human abnormal prothrombin as well as antibodies which form antibody antigen complexes with human abnormal prothrombin in the presence of such mixtures have been obtained. Immunoassay techniques are used for qualitative and quantitative determinations of these antigens in human plasma or serum. Unique methods of obtaining the antibodies are described including obtaining antibodies to native prothrombin by dissociation of antigen antibody complexes formed in the presence of calcium ions with a material having a greater affinity constant for binding with calcium ions than does prothrombin. Dissociation of the complex in this manner yields human native prothrombin antibodies which are specific and non-reactive with human abnormal prothrombin.

Abstract: A method of producing monoclonal antibodies that bind to tumor-associated gangliosides, the method comprising: (1) immunizing a host with tumor cells; (2) boosting the host with a suspension comprising a mixture of tumor cell membrane and at least one purified lactonized tumor-associated ganglioside; (3) boosting the host with an immunogen comprising a lactone of a tumor associated ganglioside adsorbed on or incorporated into a carrier; (4) fusing immunized cells from the host with myeloma cells to form hybridoma cells: (5) selecting hybridoma cells that produce antibody that binds to the ganglioside of step (3); (6) culturing the selected hybridoma cells; and (7) recovering the antibody. Hybridomas and monoclonal antibodies produced by the above-described method. A passive immunization method for treatment of tumors containing gangliosides comprising administering to a subject: (A) a pharmaceutically effective amount of an antibody produced by the above described method.

Abstract: An anti-idiotypic monoclonal antibody, which induces production of mucoid exopolysaccharide-specific antibodies which are opsonic for mucoid Pseudemonas aeruginosa. The anti-idiotypic monoclonal antibody is produced by a cell line designated C9F5 and having ATCC accession No. HB10715. The anti-idiotypic monoclonal antibody is useful as a vaccine and for diagnostic purposes.

Abstract: Disclosed are monoclonal antibodies having an affinity for endothelin-3 or a precursor thereof; a hybridoma cell which produces the monoclonal antibody; and an immunoassay of endothelin-3 and big endothelin-3, a precursor of endothelin-3, by a sandwich method or a competitive method. The monoclonal antibodies can be used as strong antagonists for endothelin-3 in various endothelin-3-related diseases, and the immunoassays make it possible to determine endothelin-3 and big endothelin-3 with high sensitivity.

Abstract: A unique anti-platelet monoclonal antibody which binds to human platelet glycoprotein IV, and various utilities of the monoclonal antibody are described.

Abstract: The subject invention relates a method for the production of monoclonal antibodies. The method utilizes an immunized antigen free animal. The invention also provides a method for the use of such monoclonal antibodies, and polyclonal antibodies derived from an immunized antigen free animal, for in vitro and in vivo clinical diagnostics and therapeutics. Also, the subject invention provides a fibrin-specific monoclonal antibody.

Abstract: This invention relates to an assay for fibrin polymers for use in the diagnosis of patients at risk of thrombosis and in monitoring the effects of treatment in such patients. More particularly, the present invention relates to an assay for soluble crosslinked fibrin polymers in patent samples involving the in vitro treatment of the sample with a proteolytic enzyme such as t-PA which generates the D-dimer fragment of soluble fibrin polymers. The amount of D-dimer formed is determined by an immunoassay specific for D-dimer. The measurement of D-dimer is thus a useful reflection of the hypercoagulability state and the test may be useful for assessing pre-thrombotic or thrombotic disorders such as myocardial infarction, pulmonary embolism and deep vein thrombosis, as well as for soluble fibrin formation in neoplastic, immune, inflammatory states, or other pathologic conditions, and for evaluations of therapy such as with anticoagulants that are used to treat these conditions.

Abstract: Disclosed herein is an anti-human myocardial C protein monoclonal antibody which is specific to human myocardial C protein and a hybridoma producing the monoclonal antibody. The monoclonal antibody of this invention is useful as a drug for the image diagnosis of heart diseases, when labelled with an enzyme, radioisotope or a fluorescent substance.

Abstract: Compositions and methods for their use are provided for preventing proliferation of remnant lens epithelial cells following extracapsular extraction. Complement-fixing monoclonal antibodies specific for lens epithelial cells are introduced into the anterior chamber of the eye. Following binding of the monoclonal antibody to any lens epithelial cells, complement is introduced into the anterior chamber effecting lysis of the remnant lens epithelial cells. The method may be used at the time of extracapsular cataract extraction or may be used subsequently to remove a second cataract resulting from proliferation of remnant lens epithelial cells.

Abstract: A human monoclonal antibody, which has prophylactic and therapeutic effect to infectious diseases caused by Pseudomonas aeruginosa of serotypes A and H classified under the Japanese Committee's Classification, and the epitope of which is located at the common structure in the O-antigen of Pseudomonas aeruginosa of serotypes A and H. A hybridoma producing said human monoclonal antibody, and processes for preparing said hybridoma and antibody are also provided.

Abstract: The present invention relates to a naturally occurring, minimally modified LDL antigen which is present in human atherosclerotic lesions as well as in the serum of a high percentage of patients with coronary artery disease. The invention also comprises antibodies reactive with the antigen, hybridoma cell lines that produce the antibodies of the inveniton, and methods for using the antibodies in the diagnosis and treatment of atherosclerotic disease.

Abstract: An anti-human papillomavirus (HPV) monoclonal antibody reactive with various types of HPVs, which is produced by a hybridoma comprising a fused cell of a mouse spleen cell from a mouse immunized with an alkali-treated HPV type 1 (HPV-1) and a mouse myeloma cell, and which is reactive with polypeptides of about 57 kilodaltons, about 160 kilodaltons and about 230 kilodaltons of HPV-1, and a process for preparing the same. The monoclonal antibody of the invention is reactive with various types of HPV and useful for diagnosis of various types of HPV infection (primary diagnosis).

Abstract: A new B-cell receptor, Bp50, a 50 kilodalton polypeptide, that functions in B-cell proliferation is described. Ligands such as lymphokines, antibody molecules or the Fv fragments of antibody molecules that bind to Bp50 and augment the proliferation of activated B-cells can be used to regulate B-cell proliferation or differentiation.

Abstract: The present invention provides novel compositions and methods useful in the diagnosis and monitoring of Gram-negative infection, especially chronic Pseudomonas aeruginosa infection associated with cystic fibrosis. Pseudomonas aeruginosa strain PAC 605 core lipopolysaccharide determinants are employed as a solid phase antigen in enzyme linked immunosorbant assays and Western blot immunoassay to measure human IgG response to P. aeruginosa infection. The novel compositions are provided in kit form for use in assay methods according to the present invention.

Abstract: A monoclonal antibody against Doxorubicin and other anthracycline derivatives, being the monoclonal antibody able to selectively recognize epitopes located in correspondence or in proximity of the aromatic D ring of the anthracycline molecule, is described.

Abstract: The present invention is directed to monoclonal antibodies, and hybridomas which produce them, which are preferentially reactive with canine lymphoma cells and insignificantly reactive with normal canine lymphocytes.

Abstract: A monoclonal antibody specific for enterohemorrhagic Escherichia coli 0157:H7 and 026:H11 is produced by immunizing BALB/c mice with a strain of E coli 0157:H7. The antibody reacts strongly by an enzyme-linked immunosorbent assay with a 13,000 dalton molecular weight outer membrane protein of strains of enterohemorrhagic Escherichia coli 0157:H7 and 026:H11.

Abstract: The present invention relates to the use of combinations of antibody therapy and chemotherapy in the treatment of malignant disease. More particularly, the invention relates to novel methods of treating patients who have malignant disease and who have shown an unresponsiveness to treatment with standard chemotherapy regimens by administering to those patients (i) an antibody that binds to the malignant cells of the patient and (ii) a chemotherapeutic agent. According to particular embodiments of the invention, anti-glycolipid antibodies are administered to patients who are subsequently treated with standard chemotherapy regimens.